Viking Therapeutics Inc. (VKTX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Viking Therapeutics Inc.

    NASDAQ: VKTX · Real-Time Price · USD
    26.98
    0.45 (1.70%)
    At close: Sep 05, 2025, 3:59 PM
    26.94
    -0.15%
    After-hours: Sep 05, 2025, 07:55 PM EDT

    Viking Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 n/a 292K 291K 296K
    Gross Profit
    		 n/a -292K -291K -296K
    Operating Income
    		 -150.92M -100.83M -70.36M -55.68M
    Interest Income
    		 n/a 15.02M 1.59M 703K
    Pretax Income
    		 -109.96M -85.89M -68.87M -54.99M
    Net Income
    		 -109.96M -85.89M -67.38M -54M
    Selling & General & Admin
    		 49.28M 37.02M 16.12M 10.7M
    Research & Development
    		 101.64M 63.81M 54.23M 44.98M
    Other Expenses
    		 n/a n/a n/a n/a
    Operating Expenses
    		 150.92M 100.83M 70.36M 55.68M
    Interest Expense
    		 n/a 88K n/a 18K
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 n/a 100.83M 70.36M 55.68M
    Income Tax Expense
    		 n/a n/a -1.49M -988K
    Shares Outstanding (Basic)
    		 109.04M 94.35M 76.83M 77.2M
    Shares Outstanding (Diluted)
    		 109.04M 94.35M 76.83M 77.2M
    EPS (Basic)
    		 -1.01 -0.91 -0.88 -0.7
    EPS (Diluted)
    		 -1.01 -0.91 -0.88 -0.7
    EBITDA
    		 -109.52M -100.83M -70.36M -55.39M
    EBIT
    		 -109.87M -100.83M -70.36M -55.68M
    Depreciation & Amortization
    		 n/a 292K 291K 296K

    Add to Watchlist